Jupiter Life Line Hospitals Ltd. (JLHL) AI Stock Analysis

• Market Cap: ₹99.22B
• Dividend Yield: 0.13%
• Average Volume (3M): 1.50K
• Price to Earnings (P/E): 51.5
• Beta (1Y): 0.30
• Revenue Growth: 18.34%
• EPS Growth: 15.25%
• Country: IN
• Employees: 4,586
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 6.70
• Shares Outstanding: 65,566,025
• 10 Day Avg. Volume: 1,433
• 30 Day Avg. Volume: 1,496
• PEG Ratio: 14.64
• Price to Book (P/B): 7.55
• Price to Sales (P/S): 8.12
• P/FCF Ratio: -151.89
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹1,627.00
• Price Target Upside: 4.98% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 67 Neutral
• Price Target: ₹1,627.00 ▲(4.98% Upside)

Jupiter Life Line Hospitals Ltd. has a strong financial foundation with consistent revenue and profit growth, which is the most significant factor. Technical analysis indicates a stable upward trend, but the high P/E ratio suggests overvaluation, impacting the overall score.

Jupiter Life Line Hospitals Ltd. Business Overview & Revenue Model

Company Description

Jupiter Life Line Hospitals Limited, a multi-specialty hospital, provides health care services under the Jupiter brand in India. The company provides treatments in the areas of bariatric surgery, breast care center, cardiac surgery, cardiology, chest medicine, dental care, dermatology, ENT, endocrinology and diabetes, gastroenterology, general surgery and minimal access surgery, HPB and surgical gastroenterology, hematology and BMT, infectious diseases, internal medicine, interventional radiology, mental health, nephrology, neurology, neurosurgery, nutrition and dietetics, Obs and gynecology, oncology, ophthalmology, organ transplant, orthopedics, pediatrics, pain clinic, plastic and cosmetic surgery, rehabilitation, rheumatology, robotic knee replacement, and urology. It also operates breast care center, chest medicine, and pain clinic departments, as well as hotel under the Fortune Park Lake City Hotel name in Thane. The company was incorporated in 2002 and is based in Mumbai, India.

How the Company Makes Money

Jupiter Life Line Hospitals Ltd. generates revenue primarily through patient admissions, which includes inpatient and outpatient services. The hospital charges fees for consultations, diagnostic tests, surgical procedures, and various therapeutic treatments. Additionally, JLHL may earn income from health insurance partnerships, where they receive reimbursements for services provided to insured patients. The company might also generate revenue from ancillary services, such as pharmacy, laboratory, and radiology services offered within their facilities. Strategic partnerships with insurance providers and corporate health programs contribute significantly to their earnings, as these collaborations often lead to increased patient volume and consistent revenue streams.

Jupiter Life Line Hospitals Ltd. Financial Statement Overview

Summary

Jupiter Life Line Hospitals Ltd. demonstrates strong financial health with consistent revenue and profit growth. The balance sheet is stable with manageable leverage, but cash flow management requires attention due to negative free cash flow growth.

Income Statement

Jupiter Life Line Hospitals Ltd. has shown consistent revenue growth over the years, with a notable increase in gross profit margins, indicating efficient cost management. The net profit margin has improved, reflecting enhanced profitability. EBIT and EBITDA margins are strong, showcasing operational efficiency.

Balance Sheet

The company has a healthy debt-to-equity ratio, indicating a balanced approach to leveraging. The return on equity is robust, suggesting effective use of shareholder funds. The equity ratio is stable, reflecting a solid financial foundation.

Cash Flow

While operating cash flow is strong, the negative free cash flow growth and ratio to net income indicate potential challenges in cash management. The operating cash flow to net income ratio is healthy, but improvements in free cash flow are needed.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	13.22B	12.62B	10.70B	8.93B	7.33B	4.86B
Gross Profit	10.74B	10.31B	8.55B	7.11B	4.07B	2.41B
EBITDA	3.44B	3.25B	2.61B	2.06B	1.50B	637.55M
Net Income	1.92B	1.93B	1.77B	729.05M	511.28M	-22.97M
Balance Sheet
Total Assets	0.00	19.05B	12.81B	9.86B	9.09B	7.89B
Cash, Cash Equivalents and Short-Term Investments	6.03B	6.03B	3.18B	1.36B	1.06B	266.46M
Total Debt	0.00	3.93B	623.41M	4.69B	4.95B	4.26B
Total Liabilities	-13.56B	5.49B	1.13B	6.22B	6.20B	5.42B
Stockholders Equity	13.56B	13.56B	11.69B	3.66B	2.94B	2.39B
Cash Flow
Free Cash Flow	0.00	-674.22M	292.26M	399.24M	452.40M	-1.18B
Operating Cash Flow	0.00	2.53B	1.15B	1.17B	1.37B	1.23B
Investing Cash Flow	0.00	-2.09B	-758.89M	-1.04B	-852.46M	-2.96B
Financing Cash Flow	0.00	3.01B	1.28B	175.00M	322.02M	1.84B

Jupiter Life Line Hospitals Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1549.75
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JLHL, the sentiment is Positive. The current price of 1549.75 is above the 20-day moving average (MA) of 1495.74, above the 50-day MA of 1453.90, and above the 200-day MA of 1491.25, indicating a bullish trend. The MACD of 21.07 indicates Negative momentum. The RSI at 62.60 is Neutral, neither overbought nor oversold. The STOCH value of 69.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:JLHL.

Jupiter Life Line Hospitals Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ASTERDM	77 Outperform	₹355.07B	108.05	―	0.71%	-53.19%	-94.01%
FORTIS	75 Outperform	₹803.28B	92.49	―	0.09%	14.04%	32.99%
MEDANTA	71 Outperform	₹362.53B	67.82	―	0.04%	15.42%	10.66%
JLHL	67 Neutral	₹99.22B	51.48	―	0.13%	18.34%	15.25%
NH	66 Neutral	₹361.91B	45.86	―	0.25%	12.09%	-2.79%
KIMS	65 Neutral	₹280.02B	74.37	―	―	24.71%	19.17%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%